Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer

Table 2 Correlation between six-transmembrane epithelial antigen of the prostate 4 expression and clinicopathological parameters in gastric cancer patients

Clinical parameters	STEAP4		P value
	Low (%)	High (%)
Age
< 60	9 (25.0)	27 (75.0)	0.5662
≥ 60	12 (20.0)	48 (80.0)
Gender
Female	6 (19.4)	25 (80.6)	0.6800
Male	15 (23.1)	50 (76.9)
T
T1-3	15 (23.8)	48 (76.2)	0.5264
T4	6 (18.2)	27 (81.8)
N
N0	7 (35.0)	13 (65.0)	0.1105
N1-N3	14 (18.4)	62 (81.8)
M
M0	21 (22.3)	73 (77.7)	0.9999
M1	0 (0)	2 (100)
Vascular invasion
No	18 (26.1)	51 (73.9)	0.1105
Yes	3 (11.1)	24 (88.9)
Clinical stage
Phase 1	2 (25.0)	6 (75.0)	0.5900
Phase 2	8 (29.6)	19 (70.4)
Phase 3	11 (18.6)	48 (81.4)
Phase 4	0 (0)	2 (100)

STEAP4: Six-transmembrane epithelial antigen of the prostate 4.